Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
Corvus Pharmaceuticals (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, has announced its participation in the 2025 Jefferies Global Healthcare Conference in New York. The company's leadership team will deliver a corporate overview presentation on Thursday, June 5, from 9:20-9:50 am ET and conduct one-on-one meetings with investors. A webcast of the presentation will be available live and accessible for 90 days after the event through the investor relations section of Corvus's website.
Corvus Pharmaceuticals (NASDAQ: CRVS), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione alla Jefferies Global Healthcare Conference 2025 a New York. Il team dirigenziale dell'azienda terrà una presentazione aziendale generale il giovedì 5 giugno, dalle 9:20 alle 9:50 ET e svolgerà incontri individuali con gli investitori. Una trasmissione web della presentazione sarà disponibile in diretta e accessibile per 90 giorni dopo l'evento nella sezione relazioni con gli investitori del sito web di Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS), una compañía biofarmacéutica en etapa clínica, ha anunciado su participación en la Conferencia Global de Salud Jefferies 2025 en Nueva York. El equipo directivo de la empresa ofrecerá una presentación corporativa el jueves 5 de junio, de 9:20 a 9:50 am ET y realizará reuniones individuales con inversores. Una transmisión en vivo de la presentación estará disponible y accesible durante 90 días después del evento a través de la sección de relaciones con inversores en el sitio web de Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS)는 임상 단계의 바이오제약 회사로서, 뉴욕에서 열리는 2025 제프리스 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사 경영진은 6월 5일 목요일 오전 9시 20분부터 9시 50분(동부시간)에 기업 개요 발표를 진행하며, 투자자들과 일대일 미팅도 가질 예정입니다. 발표 웹캐스트는 실시간으로 제공되며, 행사 후 90일 동안 Corvus 웹사이트의 투자자 관계 섹션에서 시청할 수 있습니다.
Corvus Pharmaceuticals (NASDAQ : CRVS), une société biopharmaceutique en phase clinique, a annoncé sa participation à la Jefferies Global Healthcare Conference 2025 à New York. L'équipe de direction de l'entreprise présentera un aperçu corporate le jeudi 5 juin, de 9h20 à 9h50 ET et tiendra des réunions individuelles avec des investisseurs. Une retransmission en direct de la présentation sera disponible et accessible pendant 90 jours après l'événement via la section relations investisseurs du site web de Corvus.
Corvus Pharmaceuticals (NASDAQ: CRVS), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der Jefferies Global Healthcare Conference 2025 in New York angekündigt. Das Führungsteam des Unternehmens wird am Donnerstag, den 5. Juni, von 9:20 bis 9:50 Uhr ET eine Unternehmenspräsentation halten und Einzelgespräche mit Investoren führen. Eine Webcast der Präsentation wird live verfügbar sein und 90 Tage nach der Veranstaltung über den Investor-Relations-Bereich der Corvus-Website abrufbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2025 Jefferies Global Healthcare Conference, which is being held in New York, NY. The presentation will be on Thursday, June 5 from 9:20-9:50 am ET.
A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When is Corvus Pharmaceuticals (CRVS) presenting at the 2025 Jefferies Healthcare Conference?
How can investors access Corvus Pharmaceuticals' (CRVS) presentation at the Jefferies Conference?
What type of meetings will Corvus Pharmaceuticals (CRVS) conduct at the 2025 Jefferies Conference?
What is Corvus Pharmaceuticals' (CRVS) business focus?
